What's on the label is the measured result — net peptide mass, not gross powder weight, plus RP-HPLC purity, on a lot-numbered COA for every batch.
Net peptide mass and RP-HPLC purity — a lot-numbered COA for every batch.
Net peptide mass + HPLC purity, per lot.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
Reference-code fill; Retatrutide identity verified per batch COA · 5 mg
Overview
GLP1-R-5 is the 5 mg fill-size variant within the same upstream reference code family as GLP1-R-30. The 'R' designator in the code indicates Retatrutide-class material; the '5mg' designates the per-vial fill. The 5 mg fill is more appropriate for pilot-scale research aliquot work or for distributor buyers fractionating into smaller dispensing presentations, while the 30 mg fill better matches larger-scale workflows. As with all reference-code SKUs in the metabolic catalog, the API identity, sequence, salt form, and CAS is verified against the released batch-specific COA before any order placement, and the named-API equivalent (the Retatrutide SKU) is the recommended procurement route for direct end-buyers.
Who buys this, and why
Most buyers in this category are 503A and 503B compounding pharmacies fulfilling metabolic and weight-management protocols, plus research labs investigating GLP-1 / GIP / GCG receptor pharmacology. The procurement decision usually hinges on three things: documented purity at scale, a regulatory team that can respond on destination-market questions in writing, and the ability to supply consistent counter-ion form (acetate by default) across recurring orders.
Primary buyer fit: regional distributors and re-sellers.
Specifications
Documentation available on request
Regulatory note
Reference code; verify API identity via batch-specific COA before order placement.
Frequently asked questions
The 5 mg fill in the GLP1-R-5 SKU is sized for two main workflows: (1) pilot-scale research aliquot work where the full 30 mg batch would be wasted on the experimental scale, and (2) distributor buyers who fractionate larger batches into smaller dispensing presentations and need a price-equivalent reference smaller fill. The 5 mg fill is the smallest standard size in the R-series; for buyers who need even smaller amounts, the named Retatrutide SKU offers more flexibility at 2 mg minimum.
Per-mg pricing follows the standard inverse-scale relationship, smaller fills have higher per-mg cost because the per-vial overhead (lyophilization, vial materials, QC release, packaging) is amortized across less mass. The typical cost differential between GLP1-R-5 and GLP1-R-30 is 30-50% per mg, depending on the production run and current Retatrutide market pricing. For research workflows that need small absolute quantities, the GLP1-R-5 fill is the right choice despite the per-mg premium; for distributor inventory building or for workflows planning 10+ mg dispensing presentations, GLP1-R-30 is more economical. Quote requests are answered with current pricing for both options so buyers can compare directly.
Technically yes, reconstituted Retatrutide can be aliquoted into single-use volumes and held at -20 °C between uses, the same handling guidance that applies to the named Retatrutide SKU. However, the operational reality is that the 5 mg starting amount is already quite small once reconstituted (5 mL at 1 mg/mL working concentration; 25 mL at 0.2 mg/mL), and further fractionation in-house exposes the lyophilizate or reconstituted solution to multiple manipulation cycles where contamination or potency loss can occur. For research workflows planning multiple experiments, ordering the appropriate total amount (GLP1-R-5 or GLP1-R-30 depending on need) upfront is operationally simpler than serial aliquoting from a small starting vial.
Related peptides
